C-peptide vs Nociceptin
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Nociceptin (Nociceptin/orphanin FQ) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | Nociceptin |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Connecting peptide (C-peptide) | Nociceptin/orphanin FQ |
| Molecular Weight | 3020.3 Da | 1881.1 Da |
| Half-Life | ~20-30 min | ~minutes |
| Amino Acids | 31 | 17 |
| Typical Dose | no approved analgesic dose|research-only | no approved human dose|research-only |
| Route | IV|subQ | intrathecal|intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 44 |
| Research Status | Pre-clinical | Pre-clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Nociceptin Benefits
- ✓allodynia reduction
- ✓central pain modulation
- ✓neuropathic pain research
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Nociceptin Dosing
no established human dose|research-only dosing varies
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Nociceptin Side Effects
- ⚠sedation
- ⚠dysphoria
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Nociceptin
Nociceptin is a major pain-pathway peptide in the spinal cord, brainstem, and trigeminal system. Its relevance to migraine and neuropathic pain is mainly preclinical, where receptor-selective tools are being explored.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.